Glutamine signaling specifically activates c-Myc and Mcl-1 to facilitate cancer cell proliferation and survival
-
Meng Wang,
-
Fu-Shen Guo,
-
Dai-Sen Hou,
-
Hui-Lu Zhang,
-
Xiang-Tian Chen,
-
Yan-Xin Shen,
-
Zi-Fan Guo,
-
Zhi-Fang Zheng,
-
Yu-Peng Hu,
-
Pei-Zhun Du,
-
Chen-Ji Wang,
-
Yan Lin,
-
Yi-Yuan Yuan,
-
Shi-Min Zhao,
-
Wei Xu
-
Abstract
Glutamine provides carbon and nitrogen to support the proliferation of cancer cells. However, the precise reason why cancer cells are particularly dependent on glutamine remains unclear. In this study, we report that glutamine modulates the tumor suppressor F-box and WD repeat domain-containing 7 (FBW7) to promote cancer cell proliferation and survival. Specifically, lysine 604 (K604) in the sixth of the 7 substrate-recruiting WD repeats of FBW7 undergoes glutaminylation (Gln-K604) by glutaminyl tRNA synthetase. Gln-K604 inhibits SCFFBW7-mediated degradation of c-Myc and Mcl-1, enhances glutamine utilization, and stimulates nucleotide and DNA biosynthesis through the activation of c-Myc. Additionally, Gln-K604 promotes resistance to apoptosis by activating Mcl-1. In contrast, SIRT1 deglutaminylates Gln-K604, thereby reversing its effects. Cancer cells lacking Gln-K604 exhibit overexpression of c-Myc and Mcl-1 and display resistance to chemotherapy-induced apoptosis. Silencing both c-MYC and MCL-1 in these cells sensitizes them to chemotherapy. These findings indicate that the glutamine-mediated signal via Gln-K604 is a key driver of cancer progression and suggest potential strategies for targeted cancer therapies based on varying Gln-K604 status.
-
-